Rep. Lisa McClain (R-MI) (Photo by Michael Brochstein/Sipa USA)(Sipa via AP Images)

House com­mit­tee in­ves­ti­gates FDA’s han­dling of com­mon nasal de­con­ges­tant as ef­fi­ca­cy ques­tions loom

A House pan­el is prob­ing the FDA over how it has al­lowed a com­mon in­gre­di­ent in over-the-counter cold med­ica­tions to stay on the mar­ket for decades af­ter new da­ta sug­gest­ed that it doesn’t work to treat nasal con­ges­tion.

In a let­ter sent to FDA Com­mis­sion­er Rob Califf dat­ed Sun­day, Rep. Lisa Mc­Clain (R-MI), who chairs the House Over­sight sub­com­mit­tee on health­care, asks the FDA to sched­ule a brief­ing with com­mit­tee staff to glean more in­for­ma­tion on the agency’s han­dling of oral phenyle­phrine, the ac­tive in­gre­di­ent in sev­er­al cold med­i­cines like Sudafed and Ther­aflu.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA